Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWeiqi Li

Discussion

Loading...

Member takes

Overview

Multicenter randomized controlled trial shows ruxolitinib and decitabine decrease relapse rates in AML, suggesting effective treatment options.

Key Points

  • To evaluate the impact of a combined Ruxolitinib and decitabine regimen on recurrence rates post-transplant in AML.
  • Conducted a multicenter randomized controlled trial involving patients with AML CR1.
  • Used a pretreatment regimen of Ruxolitinib combined with decitabine and modified cyclophosphamide.
  • Measured cumulative recurrence rates and overall survival post-transplant.
  • Cumulative recurrence rate was 5.26% within one year after transplantation.
  • One-year overall survival was 90.4% and progression-free survival was 87.5%.
  • The regimen had acceptable safety profiles with manageable toxicity levels.

Cite This Study

Weiqi Li (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db48https://doi.org/10.1182/blood-2025-5969
View Full Paper
Ask AI
Bookmark
Share